Bronnen:
- Doorduijn JK, Bromberg JEC. HOVON 105: rituximab bij de behandeling van het primair centraal zenuwstelsel lymfoom - een gerandomiseerde fase III-intergroupstudie. Ned Tijdschr Hematol. 2011;8:29-33.,Van der Meulen M, Dinmohamed AG, Visser O, et al. Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989-2015. Leukemia. 2017;31:1822-5.,Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol. 2006;24:1281-8. ,Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol. 2003;21:4483-8.,Rituximab bij primair centraal zenuwstelsel lymfoom. HOVON 105 PCNSL / ALLG NHL24. www.hovon.nl/trials. ,Bromberg J, Issa S, Bukanina K, et al. Effect of rituximab in primary central nervous system lymphoma – results of the randomized phase III HOVON 105/ALLG NHL 24 study. Abstract #582. Presented at the 2017 American Society of Hematology Annual Meeting, December 11, 2017; Atlanta, GA.